Limited innovation in the late-stage pipeline for insomnia
The insomnia market is heavily genericised, creating a difficult competitive environment for new drug products.
Comment & Opinion
Are decentralised clinical trials actually patient-centric?
World Contraception Day – a day to create awareness of contraception
Promise for Relmada Therapeutics’s antidepressant REL-1017, but more data required
The burden of hepatitis B and hepatitis C-related illnesses
High global prevalence of HPV in sexually active men
Could Gilead’s Trodelvy be the next TROP-2 therapy game-changer in NSCLC treatment?
New evidence shows depression as a major risk for type 2 diabetes
